Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Exploring Network Meta-Analyses (NMA) in Psoriasis

This episode, titled "Exploring Network Meta-Analyses (NMA) in Psoriasis," features panelists discussing the value and limitations of network meta-analyses as a tool for comparing multiple psoriasis therapies across different clinical trials simultaneously.

The panel opens by introducing a network meta-analysis presented at a 2026 meeting that evaluated icotrokinra against multiple biologic and oral therapies. The panel explains that while NMAs allow for a broader range of comparisons than a single MAIC, the data they generate provides a range of where a drug's efficacy is likely to fall rather than a definitive declaration of superiority over any individual comparator. In this particular analysis, icotrokinra demonstrated superiority over placebo, deucravacitinib, adalimumab, apremilast, and ustekinumab. It showed comparable performance to secukinumab, guselkumab, risankizumab, and ixekizumab, while bimekizumab and brodalumab outperformed icotrokinra in this analysis.

The panel then outlines the key methodological limitations of NMAs compared to MAICs. Unlike MAICs, NMAs do not adjust for differences in patient population demographics across studies, relying instead on assumptions that treatment effects would have behaved similarly across different trial populations. The panel cautions that higher placebo response rates in one study can make a drug appear less effective, and that overlapping confidence intervals in an NMA do not necessarily mean two drugs are equivalent, citing examples where head to head trials have subsequently demonstrated clear superiority of one agent over another despite NMA results suggesting comparability.

The panel concludes by acknowledging that both MAICs and NMAs have inherent limitations including known and unknown demographic confounders, and that head to head trials remain the gold standard for drug comparisons. However, given the significant resources required to power head to head trials sufficiently, particularly in a field where leading therapies perform at very high levels, these indirect comparison tools remain important and valuable pieces of the overall evidence puzzle.

In the next episode, "Evaluating IL-23 Inhibitors with Long-Term Data and Real-World Evidence," panelists will continue their discussion on psoriasis and highlight the complementary roles of long term extension studies and real world evidence in assessing the durability and safety of IL-23 inhibitors, and why real world data is critical for understanding how these therapies perform outside of the controlled clinical trial setting.

Videos

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Video Series

Evaluating Psoriasis Therapies using MAICs

In "Evaluating Psoriasis Therapies using MAICs," our panel delves into several recent and clinically meaningful MAIC analyses comparing biologic therapies for plaque psoriasis, examining what the data reveals about relative efficacy across treatment classes and how these analyses have been validated over time.

The panel opens by discussing a recently presented anchored MAIC comparing risankizumab to icotrokinra, an oral IL-23 receptor blocker not yet approved for psoriasis. Using risankizumab patient level data matched to icotrokinra's aggregate demographic data and adjusted for placebo response, the analysis demonstrated statistically significant superiority for risankizumab across PASI 75, 90, and 100 endpoints at weeks 4, 8, 12, and 16. The panel is careful to note that icotrokinra performed well overall, and that the superiority observed reflects the rigor of the adjusted analysis rather than a dismissal of the comparator drug.

The discussion then broadens to cover three additional MAICs conducted across different biologic classes. The first compared risankizumab to deucravacitinib, a TYK2 inhibitor, showing risankizumab superiority with a 32 to 40% delta across PASI 75, 90, and 100 endpoints. The second compared deucravacitinib to adalimumab using long term extension data rather than a placebo controlled period, demonstrating a 10 to 13% delta favoring deucravacitinib at approximately two years. The third compared guselkumab to ixekizumab over three years, finding that while the IL-17 inhibitor ixekizumab performed faster initially, guselkumab not only caught up but appeared to outperform it in the long run.

The panel highlights that the true validation of the MAIC methodology lies in the fact that dedicated head to head trials subsequently conducted for both risankizumab versus deucravacitinib and guselkumab versus ixekizumab confirmed the findings predicted by the earlier MAIC analyses. The panel also acknowledges important methodological considerations for long term MAICs, including the absence of a placebo group, population enrichment over time, and the challenge of handling missing data, while noting that certain study designs used multiple statistical analyses and placebo crossover patients to strengthen the robustness of their conclusions.

Our next episode, "Exploring Network Meta-Analyses (NMA) in Psoriasis," further explores psoriasis highlighting the utility and limitations of network meta-analyses as a complementary statistical tool for comparing multiple biologic and oral therapies simultaneously, and how findings from a recent NMA evaluating icotrokinra against several available treatments help contextualize its place within the broader IL-23 treatment landscape.

Melissa Engel, PhD, a postdoctoral fellow at Feinberg School of Medicine at Northwestern Medicine.

Social Anxiety May Influence Safety Behaviors in Teens With Food Allergy, With Melissa Engel, PhD

Adolescents with food allergy may experience 

 but also by concern about social judgment, according to findings presented at ADAA 2026. In an interview with 

, Melissa Engel, PhD, a postdoctoral fellow at Feinberg School of Medicine at Northwestern Medicine, highlighted food allergy–related social anxiety as a distinct construct that may influence both psychosocial outcomes and safety-related behaviors.

“I am really excited about this research, because to date, most of the attention in both literature and in clinical context, in terms of anxiety and food allergies [in adolescents], is really focused on the fear of having an allergic reaction…nd this construct of social anxiety is getting more at the fear of…judgment from others [and]...standing out. That is something that I see clinically all the time, yet [it] is just not really received any attention, and that would require treatment that is different than treatment for fear of having an allergic reaction.”

The study surveyed 219 adolescents (mean age, 15.89 years) using a self-report questionnaire assessing anxiety across 12 common social activities. Participants rated both fear of allergic reaction and fear of negative social evaluation using a 5-point Likert scale.

Substantial proportions of adolescents reported both types of anxiety. Across activities, 43.9% to 78.1% reported fear of allergic reaction, while 25.8% to 58.7% reported fear of negative social evaluation at similar levels. The 2 domains were moderately correlated overall, though agreement varied by context.

Fear of allergic reaction was highest in travel, restaurants with friends, and birthday parties. In contrast, fear of negative social evaluation was most prominent in birthday parties, dating, and school activities involving food. Engel noted that these differences underscore the importance of considering context when assessing adolescents with food allergy.

Engel explained that fear of allergic reaction often resembles a specific phobia, characterized by avoidance of allergens and concern about accidental exposure. Food allergy–related social anxiety, however, centers on embarrassment, reluctance to disclose allergies, and concern about being perceived as burdensome. This can lead teens to avoid social situations where their allergens are present.

Adolescence may be a particularly vulnerable period, given the importance of peer relationships and increasing independence. Engel added that social concerns may contribute to specific behaviors that could affect anaphylaxis preparedness, including choosing not to carry epinephrine to avoid drawing attention, avoiding disclosure of food allergies at restaurants or social events, declining to ask about ingredients, or hesitating to advocate for safe accommodations.

“If they're worried about judgment from their peers, it might make them more likely to take risks that aren't so safe,” she said.

The findings suggest clinicians may benefit from broadening screening beyond the fear of allergic reaction. Existing tools, such as the Scale of Food Allergy Anxiety, primarily assess fear of anaphylaxis, while validated measures for food allergy–related social anxiety are not yet available.

Engel recommends incorporating open-ended questions into clinical visits, including how food allergies affect social life or whether adolescents avoid certain situations. These discussions may help differentiate between safety-related fears and concerns about social perception.

Engel also emphasized individualized assessment, as adolescents encounter different social environments, including restaurants, sleepovers, sports, and dating. Understanding context-specific concerns may help guide counseling and behavioral strategies.

Future research will focus on developing validated screening measures and adapting cognitive behavioral interventions for food allergy–related social anxiety. Engel suggested modifying existing social anxiety treatments to include practicing disclosure of food allergies and self-advocacy in real-world settings.

“This is preliminary data,” Engel said, “[but it] hasn't really been looked at before.”

A relevant disclosure for Engel includes Mallinckrodt Hospital Products Inc.

Engel M, Onal C, Bufford J, et al. More Than Just Fear Of Allergic Reaction: Examining The Role Of Social Anxiety In Adolescents With Food Allergy. Poster presented at ADAA 2026 in Chicago from April 9 – 11.

Engel discusses ADAA 2026 findings identifying fear of social judgment as a distinct component of food allergy–related anxiety in adolescents.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Food Allergy

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include phase 3 CORALreef AddOn data on the investigational oral PCSK9 inhibitor enlicitide versus other non-statin therapies for LDL-C lowering, an FDA label update removing the age restriction for epinephrine nasal spray (neffy), phase 2 data for Sanofi's bispecific TSLP/IL-13 inhibitor lunsekimig across asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis, new joint ASH/ISTH recommendations on anticoagulant prophylaxis in pediatric patients at risk for venous thromboembolism, and positive phase 3 topline results for subcutaneously administered teprotumumab-trbw (Tepezza) via on-body injector in thyroid eye disease.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of April 5, 2026 — let's jump in!

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

The investigational oral PCSK9 inhibitor enlicitide achieved a mean LDL-C reduction of 64.6% from baseline versus 6.3%, 27.8%, and 36.5% for bempedoic acid, ezetimibe, and bempedoic acid plus ezetimibe, respectively, in the phase 3 CORALreef AddOn trial in patients with ASCVD risk on background statin therapy (all 

 <.001). The findings, presented at ACC Scientific Sessions 2026 in New Orleans, position enlicitide as a potentially potent add-on option for patients who cannot achieve LDL-C targets on statins alone, with an outcome study ongoing.

FDA Removes Age Restriction for Epinephrine Nasal Spray, With Nicole Chase, MD

The FDA eliminated the minimum age requirement for 1 mg epinephrine nasal spray (neffy), shifting prescribing guidance to a weight-based threshold of ≥33 pounds and expanding access to a broader pediatric population. The label update, announced March 27, also clarifies dosing, storage, and administration technique, including guidance that patients avoid sniffing during delivery to minimize adverse effects.

Lunsekimig Meets End Points in Asthma and CRSwNP, Misses in Atopic Dermatitis

Sanofi's lunsekimig, a bispecific agent targeting both TSLP and IL-13, met its primary and key secondary endpoints in the phase 2b AIRCULES trial in moderate-to-severe asthma and in the phase 2a DUET trial in chronic rhinosinusitis with nasal polyps, though it did not meet its primary endpoint in the exploratory phase 2b VELVET study in atopic dermatitis. Full numeric data from all 3 studies have not yet been disclosed; Sanofi has characterized respiratory indications as the primary development focus and has phase 3 COPD trials underway.

12 New Recommendations for Anticoagulant Prophylaxis in Pediatric Patients at Risk for Venous Thromboembolism

A joint ASH and ISTH expert panel published 12 evidence-based recommendations in 

 on April 8 to guide anticoagulant prophylaxis decisions in pediatric patients at risk for VTE, addressing a gap previously filled by adult-derived data. Conditional recommendations include suggesting no prophylaxis in pediatric patients with solid cancer, trauma, or critical illness, and suggesting prophylaxis for those with antiphospholipid antibody syndrome or on long-term total parenteral nutrition, among other subgroup-specific guidance.

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

A phase 3 trial of subcutaneously administered teprotumumab-trbw (Tepezza) via on-body injector met its primary endpoint in moderate-to-severe active thyroid eye disease, with 76.7% of patients achieving a ≥2 mm proptosis reduction at week 24 versus 19.6% on placebo (

 <.0001), and a mean proptosis reduction of 3.17 mm versus 0.8 mm. The results, announced by Amgen on April 6, extend the established IV efficacy profile of Tepezza to a subcutaneous delivery format that may improve accessibility for a broader patient population.

Articles

Five developments span lipid management, anaphylaxis preparedness, type 2 inflammation, pediatric thromboprophylaxis, and thyroid eye disease delivery innovation. Oral PCSK9 inhibition with enlicitide produced markedly greater LDL-C reductions than other oral non-statins on top of statins in CORALreef AddOn, with outcomes data pending. Epinephrine nasal spray labeling shifted from age-based to weight-based eligibility, broadening pediatric access. Sanofi’s lunsekimig showed phase 2 efficacy in asthma and CRSwNP but not atopic dermatitis. ASH/ISTH issued pediatric VTE prophylaxis guidance. Subcutaneous teprotumumab via on-body injector replicated proptosis benefit in phase 3.

Stay updated with the latest healthcare breakthroughs, including FDA actions, in this week’s essential news roundup.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Credit: Skin and Cancer Associates and The Center for Cosmetic Enhancement

The number of innovative approaches to an array of both common and uncommon dermatologic diseases has grown in recent years, and many dermatologists have sought to share clinical pearls related to these approaches with other clinicians in the field.

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, a session on these topics titled ‘Pearls: Diagnostic and Therapeutic’ was given by several notable speakers, 1 of whom was Brad P. Glick, DO, MPH, a board-certified dermatologist and the director of the dermatology residency training program at the Larkin Health System Palm Springs campus in Florida.

 editorial team about his portion of this session, describing several key insights on treating conditions appearing on patients’ nails, designed to help dermatology clinicians:

 Your portion of this session on diagnostic and therapeutic pearls covers nail disease within dermatology. Why did you feel the topic was important to pursue?

In our training in dermatology, I think one of the areas that doesn't necessarily get a ton of attention. While I didn't necessarily talk about a particular publication, because there are publications on this topic, I don't think nails get a lot of attention on our training. [This is] because there's just so much else going on. We have to learn about the basement membrane zone, then we apply that clinically to blistering diseases and immune mediated skin diseases. So we learn about how it treats psoriasis and eczema and lichen planus and this multitude of over 3000 diseases that we take care of in dermatology that I think probably the nails get a little neglected.

Deborah Lin, who is a resident University of Miami under the tutelage of Dr. Brian Morris, and her residency program director, a couple of years ago, published a really nice paper just vetting this, [noting] that even in programs where they have nail knowledge…our dermatology residents coming out of training and, if there's an area where they maybe feel a little bit uncomfortable, it's with nails. [This is] not only with assessment, but also with just how to do a biopsy, where to look, how to assess. So I think that was one of the main reasons why I like to provide tips.

Most of my tips are literature based, whether this relates to various topics like, let's say, the impact of biologic therapies and systemic therapies on nail diseases, whether it relates to the technique of doing an intra-lesional injection, and what that actually means. Where you're doing the injection depends largely on how you assess the nail. So those were the primary reasons, because I think we need more in our residency training programs.

Would you highlight some of the biggest takeaways that you mentioned within the session?

I think that one of the things that I talked about was the use of systemic small molecules and biologic therapies in the treatment of psoriatic disease, specifically psoriasis. You know, one of the things I highlighted is that when we're evaluating patients who have psoriatic disease, we really need to look at, first and foremost, as confirmed by some of the recent international psoriasis Council and AAD guidelines, high impact areas. The nails are critically important. So I think, as I tell my residents, if someone's there for psoriasis and their shoes and socks are still on, they need to take them off. They always need to look at all 20 nail units, because patients with nail psoriasis are three to four times more likely to develop psoriatic arthritis compared to those that really don't have nail changes associated with their psoriasis. 

I think that's important, because in addition to seeing that, we also need to be screening our patients for psoriatic arthritis. Of course, we do a test called the PEST test, which is the psoriasis epidemiology screening tool, and it's all intertwined. One of the things I talked about is not only assessing the nails in the setting of an immune mediated skin disease like psoriasis…but also, there is significant impact by a number of our biologic therapies on psoriatic nail disease. So I think a we need to hone in on that assess accordingly, not just look at it from the standpoint of making the nails look or feel better, because a lot of times we don't ask, and a lot of our patients with nail changes in psoriatic disease.

They're uncomfortable, they have mechanical issues. It impacts their quality of life, but moreover, they may be one of those 30% of individuals who actually may either have or move on to develop psoriatic arthritis. I think rapid assessment is important, and realizing that we have specific biologic therapies that hadn't been studied directly for nail diseases, including tumor necrosis factor inhibitors, which are older therapies now they're mostly biosimilars…There are other post hoc analyses from our more modern day IL-17 and IL-23 inhibitors that demonstrate not only improvement in nail disease, but perhaps we are either pre-treating or treating their active psoriatic arthritis. That was really one very important area of discussion that I discussed in my my presentations on nail tips and tricks.

One of the things I also did for the audience was spend maybe 15 of my 30 minutes just going over nail terminology and different nail findings, because they are either common signs of normal health or aging, or they may be visible markers for systemic disease. I talked a lot about nail signs in general, not specific references to literature, although I did that in my remaining time, because there are some key journal articles that have been published just in the last year that I think are critical for us in our assessments for patients with nail diseases. I did talk a lot about nail terminology and nail signs of systemic disease. One other thing that I also talked about that I thought was important, because there are some new, if you will, data or information on how we assess certain nail signs of systemic disease, and one of them is the yellow nail syndrome.

Yellow nail syndrome is not particularly common, but on the other hand, it is a potential skin sign of systemic disease, where all 20 nails take on a yellow or sometimes a yellowish green color. And one of the hallmarks the presentation of patients who have yellow nail syndrome are complete absence of their cuticles. It's very, very unique presentation. And there's a wide differential diagnosis. It can look like fungus…But what's important about this particular condition is that it involves all 20 nails. Typically, the patients will present with a yellow discoloration, or yellow green discoloration of their nails. It's important to recognize this because it may be a nail sign of systemic problem, like cardiovascular disease, pulmonary disease, and more important malignancies such as bronchogenic carcinoma.

The quotes used in this Q&A interview summary were edited for clarity.

Glick had no relevant disclosures to highlight for this session.

Glick B, et al. S005 Pearls: Diagnostic and Therapeutic. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med. 2022 Dec;54(1):694-712. doi: 10.1080/07853890.2022.2044511. PMID: 35238267; PMCID: PMC8896184.

Nail pathology remains underemphasized in dermatology training despite its diagnostic value and procedural complexity. Focused assessment of all 20 nail units is essential in psoriasis, given nail involvement’s association with increased psoriatic arthritis risk and meaningful quality-of-life impairment. Contemporary systemic agents, including IL-17 and IL-23 inhibitors, show post hoc benefits for nail disease and may address concomitant joint activity. Standardized nail terminology and pattern recognition can distinguish aging-related changes from systemic markers. Yellow nail syndrome, characterized by diffuse discoloration and absent cuticles, warrants evaluation for cardiopulmonary disease and malignancy.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Key Diagnostic and Therapeutic Pearls in Dermatology, With Brad P. Glick, DO, MPH

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Sisti discusses ethics, safety, and guardrails as patients use ChatGPT for mental health support and clinicians navigate AI’s role in psychiatry.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

AI in Psychiatry Raises Ethics Questions With Dominic Sisti, PhD

Aaron Troy, MD, MPH, is a clinical research fellow in cardiovascular medicine at Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center.

Troy discusses the recent changes to the ABCs of CVD, highlighting an increased focus on lifestyle interventions and the management of risk factors.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Arrhythmia

Strategic Alliance Partnership

Reviewing the Updated ABCs of Cardiovascular Disease Prevention, With Aaron Troy, MD, MPH

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Davies explains the future of at-home dialysis access, including policy changes and technological innovation. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Expanding Dialysis Access: Policy, Variation, and the Role of Peritoneal Dialysis

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Experts discuss interpreting genetic testing in liver disease, the role of biopsy, and how to integrate variants into clinical decision-making.

Hepatology

Putting the Pieces Together: Genetic Testing, Biopsy, and Clinical Judgment

Nicole Chase, MD, is a board-certified allergist/immunologist at St. Paul Allergy Asthma, Minneapolis VA Health Care System (part-time), and an associate professor of medicine at the University of Minnesota Medical School.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Weight-Based Dosing Informs Age Removal for Epinephrine Nasal Spray, With Nicole Chase, MD

Alberico Catapano, PhD, is the research director and head of the laboratory of lipoproteins and atherosclerosis and of the lipid clinic at MultiMedica IRCCS.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Dyslipidemia

Robert Gish, MD, is the Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania. He is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University. In addition, he is the Medical Director of the American Pacific Health Foundation.

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Genetic Panels in Hepatology: Identifying the Right Patients

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Biologics Across the Airway: Selection, Remission Goals, and Real-World Barriers

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.


Anjali Vaidya, MD, is the director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program and the Pulmonary Hypertension Fellowship at Temple University Hospital and a professor of medicine at Temple University

Vaidya discusses the 2022 pulmonary arterial hypertension guidelines and how they can be made more accessible for clinicians just entering the field.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Latest News

Exploring Network Meta-Analyses (NMA) in Psoriasis

Evaluating Psoriasis Therapies using MAICs

Social Anxiety May Influence Safety Behaviors in Teens With Food Allergy, With Melissa Engel, PhD

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Key Diagnostic and Therapeutic Pearls in Dermatology, With Brad P. Glick, DO, MPH